These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27567865)

  • 21. Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer's disease.
    Vangavaragu JR; Valasani KR; Gan X; Yan SS
    Eur J Med Chem; 2014 Apr; 76():506-16. PubMed ID: 24602793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism.
    Saito T; Takaki Y; Iwata N; Trojanowski J; Saido TC
    Sci Aging Knowledge Environ; 2003 Jan; 2003(3):PE1. PubMed ID: 12844556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.
    Eckman EA; Eckman CB
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1101-5. PubMed ID: 16246055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.
    Hemming ML; Selkoe DJ; Farris W
    Neurobiol Dis; 2007 Apr; 26(1):273-81. PubMed ID: 17321748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.
    Xiang Y; Bu XL; Liu YH; Zhu C; Shen LL; Jiao SS; Zhu XY; Giunta B; Tan J; Song WH; Zhou HD; Zhou XF; Wang YJ
    Acta Neuropathol; 2015 Oct; 130(4):487-99. PubMed ID: 26363791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a possible role of Stigmatella aurantiaca ACE in Aβ peptide degradation: a molecular modeling approach.
    Jalkute CB; Sonawane KD
    J Mol Microbiol Biotechnol; 2015; 25(1):26-36. PubMed ID: 25677850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Ageing and Oxidative Stress in Regulation of Amyloid-Degrading Enzymes and Development of Neurodegeneration.
    Nalivaeva NN; Turner AJ
    Curr Aging Sci; 2017; 10(1):32-40. PubMed ID: 27834125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
    Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
    J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leptin inhibits amyloid β-protein degradation through decrease of neprilysin expression in primary cultured astrocytes.
    Yamamoto N; Tanida M; Ono Y; Kasahara R; Fujii Y; Ohora K; Suzuki K; Sobue K
    Biochem Biophys Res Commun; 2014 Feb; 445(1):214-7. PubMed ID: 24508800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simvastatin and atorvastatin facilitates amyloid β-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways.
    Yamamoto N; Fujii Y; Kasahara R; Tanida M; Ohora K; Ono Y; Suzuki K; Sobue K
    Glia; 2016 Jun; 64(6):952-62. PubMed ID: 26875818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?
    Nalivaeva NN; Beckett C; Belyaev ND; Turner AJ
    J Neurochem; 2012 Jan; 120 Suppl 1():167-185. PubMed ID: 22122230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.
    Caccamo A; Oddo S; Sugarman MC; Akbari Y; LaFerla FM
    Neurobiol Aging; 2005 May; 26(5):645-54. PubMed ID: 15708439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
    Devi L; Ohno M
    Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neprilysin and amyloid beta peptide degradation.
    Hersh LB; Rodgers DW
    Curr Alzheimer Res; 2008 Apr; 5(2):225-31. PubMed ID: 18393807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metallostasis and amyloid β-degrading enzymes.
    Grasso G; Giuffrida ML; Rizzarelli E
    Metallomics; 2012 Aug; 4(9):937-49. PubMed ID: 22832870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accumulation of murine amyloid-β mimics early Alzheimer's disease.
    Krohn M; Bracke A; Avchalumov Y; Schumacher T; Hofrichter J; Paarmann K; Fröhlich C; Lange C; Brüning T; von Bohlen Und Halbach O; Pahnke J
    Brain; 2015 Aug; 138(Pt 8):2370-82. PubMed ID: 25991605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease.
    Rajasekhar K; Chakrabarti M; Govindaraju T
    Chem Commun (Camb); 2015 Sep; 51(70):13434-50. PubMed ID: 26247608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.